Finance > Venture Deals Database > Venture Transactions Database > Monthly Deals (All) > November 2007 VC Transactions
Tranzyme Pharma

Tech Company Financing Transactions

Tranzyme Pharma Funding Round

Tranzyme Pharma, operating out of Durham, scored $20 million in investment from BDC Venture Capital, H.I.G. Capital and Quaker Partners.

Transaction Overview

Company Name

Tranzyme Pharma

Announced On

11/1/2007

Transaction Type

Venture Equity

Amount

$20,000,000

Round

Undisclosed

Investors

BDC Venture Capital (Lead Investor)

H.I.G. Capital (Lead Investor) (Aaron Davidson)

Quaker Partners (Lead Investor) (Brend Gavin)

Thomas, McNerny & Partners (Lead Investor) (Alexander Zisson)

Proceeds Purpose

Tranzyme intends to use this funding to further advance clinical development of its breakthrough GI drugs.

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

5001 South Miami Blvd. 300
Durham, NC 27703
USA

Phone

(919) 474-0020

Website

www.tranzyme.com

Email Address

[email protected]

Overview

Tranzyme Pharma (NASDAQ: TZYM) is a leading biopharmaceutical company developing novel orally bioavailable, small molecule therapeutics for the treatment of gastrointestinal (GI) diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Linda Grais

Chief Financial Officer

Michael Byrnes

Browse more venture capital transactions:

Prev: 11/1/2007: Asteres venture capital transaction
Next: 11/1/2007: eXelate venture capital transaction

Share this article

News on VC Transactions

We do our best to document every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary